• Citer

'In silico' oncology for clinical decision making in the context of nephroblastoma.

par Graf, N;Hoppe, A;Georgiadi, E Ch;Belleman, R;Desmedt, Christine ;Dionysiou, D D;Erdt, M;Jacques, J;Kolokotroni, E A;Lunzer, A;Tsiknakis, M;Stamatakos, G S
Référence Klinische PÉadiatrie, 221, 3, page (141-149)
Publication Publié, 2009

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials) -- an Integrated Project, partly funded by the EC (FP6-2005-IST-026996)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients. Cancer treatment optimization is the main goal of the system. The document refers to the technology of the system and the clinical requirements and the types of medical data needed for exploitation in the case of nephroblastoma. The outcome of an initial step towards the clinical adaptation and validation of the system is presented and discussed. Use of anonymized real data before and after chemotherapeutic treatment for the case of the SIOP 2001/GPOH nephroblastoma clinical trial constitutes the basis of the clinical adaptation and validation process. By using real medical data concerning nephroblastoma for a single patient in conjunction with plausible values for the model parameters (based on available literature) a reasonable prediction of the actual tumour volume shrinkage has been made possible. Obviously as more and more sets of medical data are exploited the reliability of the model "tuning" is expected to increase. The successful performance of the initial combined ACGT Oncosimulator platform, although usable up to now only as a test of principle, has been a particularly encouraging step towards the clinical translation of the system, being the first of its kind worldwide.